FOXO4-DRI

Most Common Uses

Senolytic Therapy for Age-Related Diseases

FOXO4-DRI is explored for its ability to selectively eliminate senescent cells, which accumulate with age and contribute to tissue dysfunction. The peptide disrupts the FOXO4-p53 interaction, promoting apoptosis in these cells. Preclinical models suggest potential benefits in improving tissue function for conditions such as osteoarthritis and cardiovascular disease.

Regenerative Medicine

Research into FOXO4-DRI includes its role in enhancing tissue regeneration. By clearing senescent cells, the peptide may foster an environment conducive to stem cell activity and tissue repair. This is particularly relevant for aged tissues, such as the liver, heart, and skeletal muscle, where regenerative capacity naturally diminishes.

Cancer Research

FOXO4-DRI is under investigation for its potential in cancer therapy. Senescent cells in the tumor microenvironment can promote tumor growth, and by targeting these cells, the peptide may slow cancer progression or enhance the effectiveness of existing treatments. These studies remain in early stages.

Anti-Aging and Longevity Studies

The peptide is a significant focus in longevity research due to its ability to reduce senescent cell burden, which is linked to aging phenotypes. In animal models, FOXO4-DRI has shown potential to improve healthspan by restoring organ function and reducing age-related inflammation.

Neurodegenerative Disease Research

Emerging research suggests FOXO4-DRI may have applications in neurodegenerative conditions, such as Alzheimer’s disease. By eliminating senescent cells in the brain, the peptide could help reduce inflammation and neuronal damage, although its use in humans is still being studied.

Mechanism of Action

FOXO4-DRI is engineered to target senescent cells, which accumulate with age and contribute to various age-related conditions. Its mechanism of action centers on disrupting specific protein interactions to induce programmed cell death in these cells.

The peptide, a D-retro-inverso (DRI) isoform, mimics the structure of the FOXO4 protein but consists of D-amino acids arranged in reverse sequence. This design enhances its stability against enzymatic degradation, allowing prolonged activity in the body. FOXO4-DRI specifically binds to the FOXO4 protein, which normally interacts with p53, a tumor suppressor protein, in senescent cells. This interaction typically maintains cell cycle arrest, preventing apoptosis and allowing senescent cells to persist.

FOXO4-DRI competes with endogenous FOXO4 for binding to p53. By displacing FOXO4, the peptide disrupts the FOXO4-p53 complex, freeing p53 to activate pro-apoptotic pathways. This shift triggers programmed cell death selectively in senescent cells, which rely on the FOXO4-p53 interaction for survival, while sparing healthy cells that do not exhibit this dependency.

The selective elimination of senescent cells reduces the secretion of pro-inflammatory factors, known as the senescence-associated secretory phenotype (SASP), which contributes to tissue dysfunction and aging. In preclinical studies, this mechanism has shown promise in restoring tissue function and mitigating age-related phenotypes in animal models. The peptide’s targeted approach and enhanced stability make it a compelling candidate for therapeutic applications, though further research is needed to confirm its effects in humans.

Structure and Pharmacology

The peptide consists of a sequence of 46 D-amino acids arranged in a retro-inverso configuration, meaning the sequence is reversed compared to the native FOXO4 protein segment it targets. Its molecular formula is C₂₂₈H₃₈₈N₈₆O₆₄, with a molecular weight of 5358 g/mol. The use of D-amino acids, which are mirror images of naturally occurring L-amino acids, renders the peptide resistant to enzymatic breakdown, extending its duration in biological systems. This structural design allows FOXO4-DRI to effectively interact with its target, the FOXO4 protein, while maintaining stability in physiological environments.

FOXO4-DRI exerts its pharmacological effects through selective targeting of senescent cells, which accumulate with age and contribute to tissue dysfunction. The peptide functions as a competitive inhibitor, binding to the FOXO4 protein and disrupting its interaction with p53, a tumor suppressor protein. This disruption triggers apoptosis specifically in senescent cells, which depend on the FOXO4-p53 complex for survival, while sparing healthy cells. The resulting clearance of senescent cells reduces the secretion of pro-inflammatory factors associated with the senescence-associated secretory phenotype (SASP), potentially alleviating inflammation and improving tissue function.

The peptide’s D-retro-inverso structure enhances its pharmacokinetic profile. Its resistance to proteases prolongs its half-life compared to peptides composed of L-amino acids, though precise half-life data in humans remain limited. In preclinical studies, FOXO4-DRI has demonstrated the ability to distribute to tissues with high senescent cell populations, such as aged organs, and promote functional restoration in models of age-related conditions. The peptide is typically administered via injection in experimental settings, with ongoing research exploring optimal dosing and delivery methods. While promising in animal models, the pharmacological effects in humans require further investigation through clinical trials to establish safety, efficacy, and therapeutic potential.

Dosages

FOXO4-DRI has been primarily evaluated in preclinical research, with limited data on human dosing. The dosages used in experimental settings provide insight into its administration, though these are not yet established for clinical use.

FOXO4-DRI is typically administered via intraperitoneal or intravenous injection. Doses in these studies often range from 5 to 10 mg/kg of body weight, given as a single injection or repeated over several days, depending on the experimental design. For example, in research exploring age-related tissue dysfunction, mice received doses of approximately 5 mg/kg every other day for a total of three administrations, showing effects like improved tissue function and reduced senescent cell burden.

Human dosing information remains unavailable, as FOXO4-DRI has not progressed to clinical trials with published results. The translation of preclinical doses to humans requires careful consideration of factors like body surface area, metabolism, and peptide stability, which have not been fully characterized for this compound. Researchers emphasize that the peptide’s D-retro-inverso structure, which enhances resistance to enzymatic degradation, may influence dosing frequency compared to other peptides.

Ongoing studies aim to refine dosing regimens and delivery methods to optimize therapeutic outcomes. Until clinical data emerge, specific dosage recommendations for human use cannot be provided, and further research is needed to establish safe and effective protocols.

Warnings and Cautions

Limited Human Data

FOXO4-DRI has not been approved for clinical use, and its safety profile in humans is not established. Preclinical studies in animal models have shown promising results, but these findings may not fully translate to human physiology. Potential risks, including off-target effects or unexpected toxicity, remain uncharacterized in human populations.

Potential Side Effects

While specific side effects in humans are unknown, the peptide’s mechanism of inducing apoptosis in senescent cells could potentially affect healthy cells or tissues if not precisely targeted. Preclinical studies have not reported significant adverse effects at tested doses, but the possibility of immune responses, inflammation, or unintended cellular damage cannot be ruled out without further research.

Experimental Administration

In research settings, FOXO4-DRI is administered via injection, typically intraperitoneal or intravenous, in animal models. The safety of these delivery methods in humans, as well as optimal dosing schedules, remains unstudied. Improper administration or unverified dosing could lead to reduced efficacy or unforeseen complications.

Lack of Regulatory Approval

FOXO4-DRI is not approved by any regulatory authority for therapeutic use. Its application is restricted to controlled research environments. People should avoid using or obtaining the peptide from unverified sources, as unregulated products may pose risks of contamination, incorrect formulation, or unknown purity.

Need for Further Research

The long-term effects of FOXO4-DRI, including its impact on tissue homeostasis and potential interactions with other medications or conditions, are not well understood. Researchers caution that until clinical trials provide comprehensive data, the peptide should be considered an experimental agent with inherent uncertainties.

Research & Clinical Trials

FOXO4-DRI Selectively Clears Senescent Cells From Expanded Chondrocytes

The study concluded that FOXO4-DRI, a senolytic peptide designed to selectively induce apoptosis in senescent cells, is effective in removing senescent chondrocytes that accumulate during the in vitro expansion process commonly used in autologous chondrocyte implantation (ACI). Specifically, when applied to extensively expanded chondrocytes at population doubling level 9 (PDL9), which simulate cells prepared for implantation, FOXO4-DRI significantly reduced the number of senescence-associated β-galactosidase-positive cells and decreased the expression of senescence-associated secretory phenotype (SASP) factors. Importantly, this effect was selective, as FOXO4-DRI did not significantly impact the viability or characteristics of minimally expanded chondrocytes at PDL3. Despite the successful reduction in senescent cell burden and pro-inflammatory secretions, the treatment did not lead to improved cartilage-forming capacity in standard 3D pellet cultures. The quality and quantity of newly generated cartilage remained similar to untreated controls, indicating that while FOXO4-DRI may improve the biological profile of the expanded chondrocyte population, it does not on its own enhance their regenerative function. These results suggest that senolytic therapy may be a valuable tool for improving cell quality in ACI, but additional interventions will likely be necessary to fully restore or boost the chondrogenic potential of extensively cultured chondrocytes. Further investigation is warranted to explore combinatory approaches that could both eliminate senescent cells and rejuvenate or enhance chondrocyte functionality for more consistent and effective cartilage repair. [1]

FOXO4-DRI Restores Testosterone by Targeting Senescent Leydig Cells

The study concluded that FOXO4 plays a critical role in maintaining the survival of senescent Leydig cells, which are central to the development of male late-onset hypogonadism (LOH). Specifically, FOXO4 is selectively expressed in human Leydig cells and becomes predominantly localized in the nucleus with age, a shift associated with decreased testosterone synthesis. In both human tissue and an in vitro mouse Leydig cell model, nuclear FOXO4 was linked to increased expression of senescence markers and reduced levels of key enzymes involved in testosterone production. The study showed that disrupting the interaction between FOXO4 and p53 using FOXO4-DRI, a senolytic peptide, selectively triggered apoptosis in senescent Leydig cells without affecting healthy ones. In aged mice, FOXO4-DRI treatment improved the testicular microenvironment and significantly restored testosterone secretion, suggesting a rejuvenation of testicular function. Overall, the findings demonstrate that targeting FOXO4 with FOXO4-DRI may be a promising therapeutic strategy to eliminate senescent Leydig cells and alleviate age-related testosterone deficiency in men, offering a potential alternative to traditional testosterone replacement therapy. [2]